Rare Daily Staff
Genetic testing company GeneDx announced the launch of GeneDx Discover, a first-of-its-kind data visualization tool that provides biopharmaceutical companies access to deidentified and aggregated genetic data to improve all stages of drug development.
The new offering is part of GeneDx’s ongoing investment to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery, the company said.
On average, developing a new therapy costs $2.6 billion and takes 12 years. The high cost in part is driven by a 90 percent rate of failure. Genetic data can significantly enhance the therapeutic development process, including reducing costs, accelerating timelines, and increasing success rates.
With more than 700,000 clinical exomes and genomes, GeneDx’s dataset is one of the most sophisticated in the industry and can now be leveraged as a solution for biopharmaceutical companies to drive evidence-based decision-making and accelerate the development of new treatments.
GeneDx Discover is a self-service tool that leverages real-world data to enable a deeper understanding of the characteristics of target patient populations. It combines disease prevalence and phenotypic information, alongside variant-level details, unlocking a deeper understanding of the size and unique characteristics of the total addressable market for genetically-defined disease cohorts, and obtaining variant-level resolution to define the cohort.
Through GeneDx Discover, partners have access to demographics, geographic disease distribution, variant information and the ability to filter searches by Human Phenotype Ontology (HPO) to refine cohorts based on specific phenotypic features.
“GeneDx Discover is a data-driven solution that empowers our biopharma partners to better understand the genetic underpinnings of diseases, their prevalence in diverse patient populations and accelerate the development of targeted therapies—helping bring effective treatments to more patients, faster,” said Melanie Duquette, chief growth officer at GeneDx.
Stay Connected
Sign up for updates straight to your inbox.